Terumo Corporation Reports Strong Financial Growth
I'm PortAI, I can summarize articles.
Terumo Corporation (TRUMF) reported strong Q2 earnings for the six months ending September 30, 2025, with revenue of ¥534.9 billion, a 5.2% year-on-year increase. Growth was driven by overseas markets, particularly in the Americas and Europe. The Cardiac and Vascular Company and Blood and Cell Technologies Company contributed significantly, with revenue increases of 5.2% and 9.2%, respectively. Adjusted operating profit rose by 10% to ¥114.4 billion. Terumo remains optimistic, revising its full-year revenue and profit guidance upward, focusing on global expansion and product enhancement in the medical technology sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments